# DESCRIPTION

## GOVERNMENT RIGHTS CLAUSE

- acknowledge government support

## FIELD OF THE INVENTION

- define field of medicine

## BACKGROUND

- describe retinitis pigmentosa
- explain genetic causes of RP
- introduce CRISPR technology

## SUMMARY OF THE INVENTION

- outline method of treatment
- describe CRISPR protein and guide RNA
- summarize in vivo genomic editing

## DETAILED DESCRIPTION OF THE INVENTION

- cite references
- define terms
- describe administering routes
- define modulation
- define pharmaceutically acceptable carriers
- define promote
- define subject
- define therapeutically effective amount
- describe retinitis pigmentosa
- discuss current mutation-focused approaches
- introduce CRISPR gene editing tools
- describe rhodopsin mutations
- hypothesize selective ablation of RhoS334

### Genomic Editing.

- introduce genomic editing
- describe site-specific chromosomal integration
- introduce ZFNs and TALENs
- describe ZFNs-based genome editing
- describe NHEJ repair
- describe HDR with donor template
- limitations of ZFNs and TALENs
- introduce CRISPR-Cas system
- describe CRISPR-Cas mechanism
- describe gRNA design
- describe Cas9-induced DSBs
- describe NHEJ-mediated indel mutations
- describe HDR with donor template
- advantages of CRISPR-Cas system
- describe clinical applicability
- describe AAV-CRISPR system
- describe SaCas9 system
- describe proof-of-concept of prophylactic prevention
- describe CRISPR/Cas9 technology
- describe method of treatment
- describe therapeutic vectors
- describe in vivo method of genomic editing
- describe in vitro method of genomic editing
- describe composition including CRISPR protein and gRNA

### Animal Model

- introduce S334ter-line-3 rat model

### CRISPR/Cas9 Constructs, Generally

- motivate CRISPR/Cas9 for retinal degeneration

### CRISPR/Cas9 Constructs, Specifically

- design gRNA for rhodopsin gene knockout

### Methods

- design CRISPR/Cas9/guide-RNA constructs
- inject constructs into S334ter-3 rats
- evaluate photoreceptor preservation
- sort retinal cells by mCherry reporter expression
- perform immunohistochemical evaluation
- design gRNAs into px330 vectors
- determine Cas9 cleavage efficiency
- describe animal procedures
- process retinal cells and MSCs
- perform immunofluorescent staining and confocal microscopy
- evaluate RhoS334 disruption in vivo
- confirm genomic sequences resulting from RhoS334-selective cleavage
- determine indel frequency
- evaluate photoreceptor preservation following RhoS334 ablation
- assess retinal phenotype
- observe PR rescue
- confirm absence of RHOS334 from PR cell bodies
- evaluate retinal synapse preservation following RhoS334 ablation
- preserve dendritic arborization of rod-bipolar cells
- preserve synaptic density between second-order inner retinal neurons and PRs
- quantify PR density and visual function in RhoS334 treated retinas
- assess visual acuity
- propose dual AAV vectors
- describe Eosomes
- describe peptide for ocular delivery (POD)
- describe liposome-mediated delivery of Cas9 protein
- discuss proof of principle for in vivo allele-specific ablation
- discuss translational limitations of current methods
- discuss broader implications of CRISPR/Cas9 for treating inherited adRP

